Edgewise Therapeutics, Inc. 8-K

What Happened Edgewise Therapeutics, Inc. (EWTX) filed an 8-K on June 5, 2026 reporting the results of its Annual Meeting held June 4, 2026. Three Class II director nominees — Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D. — were elected to serve until the 2029 annual meeting. Stockholders also ratified KPMG LLP as the company’s independent registered public accounting firm for the 2026 fiscal year and approved, on an advisory (non-binding) basis, the compensation of the company’s named executive officers.

Key Details

• Directors elected and vote totals:
  • Laura Brege: For 87,300,827; Withheld 3,822,867
  • Badreddin Edris, Ph.D.: For 64,082,681; Withheld 27,041,013
  • Jonathan Root, M.D.: For 59,213,781; Withheld 31,909,913
• Auditor ratification: KPMG LLP ratified — For 99,637,228; Against 1,123; Abstain 578,031
• Advisory vote on executive compensation: Approved — For 87,055,111; Against 3,491,326; Abstain 577,257
• Each elected director will serve until the 2029 annual meeting (or until a successor is elected and qualified).

Why It Matters These results confirm the company’s board composition through 2029, which affects governance and strategic oversight. Ratifying KPMG maintains auditor continuity for fiscal 2026, important for financial reporting and audits. The advisory approval of executive pay signals shareholder support for management compensation, though it is non-binding.